Sentinel Safety Surveillance Not Ideal For Every Product, Reports Find
Executive Summary
Before considering whether to use its nascent Sentinel safety surveillance system, FDA should see whether traditional methods might work just as well, according to two reports commissioned by the agency
You may also be interested in...
Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?
FDA plans to launch two "mini-Sentinel" pilot projects as the next steps towards building the active surveillance capability called for under the FDA Amendments Act of 2007, Sentinel Initiative Scientific Lead Judith Racoosin told a Sept. 2 Institute of Medicine meeting focused on the drug safety system post-FDAAA
Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?
FDA plans to launch two "mini-Sentinel" pilot projects as the next steps towards building the active surveillance capability called for under the FDA Amendments Act of 2007, Sentinel Initiative Scientific Lead Judith Racoosin told a Sept. 2 Institute of Medicine meeting focused on the drug safety system post-FDAAA
Postmarketing Requirements Will Be "Studies" Unless "Trials" Are Needed, FDA Says
Draft guidance lays out the FDAAA-mandated distinction, but also suggests that the agency continues to be much more comfortable with clinical trials than observational studies.